A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”
- DOI
- 10.1007/s13555-025-01627-4
- Published
- 2025-12-29
- Container
- Dermatology and Therapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-025-01627-4,
title = {A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”},
author = {Sonja Ständer and Andreas Pinter and Firas G. Hougeir and Patricia Guyot and Yingxin Xu and Amy H. Praestgaard and Nick Freemantle and Ana B. Rossi and Gaëlle Bégo‑Le‑Bagousse and Zhixiao Wang and Kerry Noonan and Mike Bastian},
year = {2025},
journal = {Dermatology and Therapy},
doi = {10.1007/s13555-025-01627-4},
url = {https://doi.org/10.1007/s13555-025-01627-4}
}RIS
TY - JOUR TI - A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’” AU - Sonja Ständer AU - Andreas Pinter AU - Firas G. Hougeir AU - Patricia Guyot AU - Yingxin Xu AU - Amy H. Praestgaard AU - Nick Freemantle AU - Ana B. Rossi AU - Gaëlle Bégo‑Le‑Bagousse AU - Zhixiao Wang AU - Kerry Noonan AU - Mike Bastian PY - 2025 JO - Dermatology and Therapy DO - 10.1007/s13555-025-01627-4 UR - https://doi.org/10.1007/s13555-025-01627-4 ER -
APA
Ständer, S., Pinter, A., Hougeir, F. G., Guyot, P., Xu, Y., Praestgaard, A. H., Freemantle, N., Rossi, A. B., Bégo‑Le‑Bagousse, G., Wang, Z., Noonan, K., & Bastian, M. (2025). A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”. Dermatology and Therapy. https://doi.org/10.1007/s13555-025-01627-4
Source records
- crossref · retrieved 2026-09-27T07:48:52.110Z